Samsara Bio Capital, LLC Eliem Therapeutics, Inc. Transaction History
Samsara Bio Capital, LLC
- $194 Million
- Q2 2024
A detailed history of Samsara Bio Capital, LLC transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Samsara Bio Capital, LLC holds 3,261,393 shares of ELYM stock, worth $26 Million. This represents 11.93% of its overall portfolio holdings.
Number of Shares
3,261,393Holding current value
$26 Million% of portfolio
11.93%Shares
1 transactions
Others Institutions Holding ELYM
# of Institutions
46Shares Held
49.9MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$251 Million3.37% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.9MShares$31.2 Million0.91% of portfolio
-
Janus Henderson Group PLC London, X03.25MShares$26 Million0.01% of portfolio
-
Boxer Capital, LLC San Diego, CA2.6MShares$20.8 Million1.03% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.67MShares$13.3 Million1.62% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $212M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...